Back to results
US 2023/0063093 A1Published application
Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
AssigneesSynlogic Operating Company, Inc., Ginkgo Bioworks, Inc.
InventorsDylan Alexander Carlin, Vincent M. Isabella, Jonathan McMurry, Theodore Carlton Moore, III, Mylene Perreault, Seth Ritter, Nathan Schmidt, Mark Simon
Life of this patent
Estimating the term…
Abstract
The present disclosure provides host cells, e.g., bacterial cells, that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with methionine metabolism in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with methionine metabolism, such as homocystinuria.
Claims28
A recombinant bacterial cell comprising:
- a heterologous methionine decarboxylase (metDC) gene operably linked to a promoter, wherein the heterologous metDC gene encodes a polypeptide comprising SEQ ID NO:
- 1048.
Dependencies are inferred from the claim text.